Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 17,300 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 17,300 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $28.28, for a total transaction of $489,244.00. Following the sale, the chief operating officer now directly owns 61,563 shares of the company's stock, valued at $1,741,001.64. This represents a 21.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Monday, June 9th, Eben Tessari sold 10,319 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.38, for a total value of $313,491.22.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.46, for a total value of $472,312.76.
• On Monday, May 19th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $26.41, for a total value of $316,920.00.
• On Monday, April 14th, Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $20.48, for a total value of $245,760.00.

Kiniksa Pharmaceuticals International Stock Down 0.1%

Shares of NASDAQ KNSA traded down $0.02 during trading hours on Wednesday, hitting $27.93. The company had a trading volume of 487,811 shares, compared to its average volume of 635,070. Kiniksa Pharmaceuticals International, plc has a 1-year low of $17.38 and a 1-year high of $30.69. The firm's 50 day moving average is $25.46 and its 200-day moving average is $22.25. The stock has a market capitalization of $2.04 billion, a P/E ratio of -111.72 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The company's revenue for the quarter was up 72.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.25) earnings per share. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently made changes to their positions in the business. Nuveen LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $16,992,000. Acadian Asset Management LLC raised its position in shares of Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after purchasing an additional 651,700 shares during the period. Braidwell LP raised its position in shares of Kiniksa Pharmaceuticals International by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after purchasing an additional 557,934 shares during the period. AQR Capital Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after buying an additional 294,319 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Kiniksa Pharmaceuticals International by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after buying an additional 277,827 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on KNSA. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Saturday. Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, April 16th. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Finally, Citigroup began coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of "Buy" and a consensus price target of $38.80.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.